• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

三氟尿苷/替匹嘧啶导致肾功能受损的转移性结直肠癌患者出现严重全血细胞减少：一例报告

Severe pancytopenia caused by trifluridine/tipiracil in patients with metastatic colorectal cancer and an impaired renal function: A case report.

作者信息

Shibutani Masatsune, Okazaki Yuki, Kashiwagi Shinichiro, Nagahara Hisashi, Fukuoka Tatsunari, Iseki Yasuhito, Maeda Kiyoshi, Hirakawa Kosei, Ohira Masaichi

机构信息

Department of Gastroenterological Surgery Osaka City University Graduate School of Medicine Osaka Japan.

Department of Breast and Endocrine Surgery Osaka City University Graduate School of Medicine Osaka Japan.

出版信息

Clin Case Rep. 2022 Mar 3;10(3):e05544. doi: 10.1002/ccr3.5544. eCollection 2022 Mar.

DOI:10.1002/ccr3.5544
PMID:35280098
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8894575/
Abstract

Although the incidence of hematological toxicity due to Trifluridine/tipiracil (FTD/TPI) treatment is high, the incidence of severe adverse events has been reported to be relatively low. However, it should be noted that patients with renal impairment are prone to severe hematological adverse events.

摘要

尽管曲氟尿苷/替匹嘧啶（FTD/TPI）治疗导致血液学毒性的发生率较高，但据报道严重不良事件的发生率相对较低。然而，应注意的是，肾功能损害患者易发生严重的血液学不良事件。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/8894575/c800d8389eb5/CCR3-10-e05544-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/8894575/c800d8389eb5/CCR3-10-e05544-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cfa2/8894575/c800d8389eb5/CCR3-10-e05544-g002.jpg

相似文献

1
Severe pancytopenia caused by trifluridine/tipiracil in patients with metastatic colorectal cancer and an impaired renal function: A case report.三氟尿苷/替匹嘧啶导致肾功能受损的转移性结直肠癌患者出现严重全血细胞减少：一例报告
Clin Case Rep. 2022 Mar 3;10(3):e05544. doi: 10.1002/ccr3.5544. eCollection 2022 Mar.
2
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.来自转移性胃癌或胃食管结合部癌和转移性结直肠癌患者的 III 期研究的替氟尿苷/替匹嘧啶的汇总安全性分析。
ESMO Open. 2022 Dec;7(6):100633. doi: 10.1016/j.esmoop.2022.100633. Epub 2022 Nov 28.
3
Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study.肾功能损害是 REGOTAS 研究转移性结直肠癌患者接受三氟尿苷/替匹嘧啶治疗不良事件的风险因素。
Sci Rep. 2023 Oct 20;13(1):17931. doi: 10.1038/s41598-023-45244-7.
4
Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer.替氟尿苷/盐酸拓扑替康单药治疗在临床实践中的安全性概况：转移性结直肠癌患者德国同情用药项目的结果。
BMC Cancer. 2018 Nov 16;18(1):1124. doi: 10.1186/s12885-018-5063-5.
5
A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment.一项评估晚期实体瘤和不同程度肾功能损害患者中替氟尿苷/替匹嘧啶安全性和药代动力学的 I 期、开放性研究。
Cancer Chemother Pharmacol. 2021 Sep;88(3):485-497. doi: 10.1007/s00280-021-04308-z. Epub 2021 Jun 7.
6
The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting.真实世界中老年转移性结直肠癌患者接受替氟尿苷/替匹嘧啶治疗的疗效和安全性。
Anticancer Res. 2021 Dec;41(12):6211-6216. doi: 10.21873/anticanres.15440.
7
A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer.三线瑞戈非尼联合替匹嘧啶/氟尿嘧啶治疗转移性结直肠癌的 I 期剂量递增研究。
Future Oncol. 2021 Sep;17(25):3309-3319. doi: 10.2217/fon-2021-0278. Epub 2021 May 17.
8
Effectiveness, safety, and prognostic factors of trifluridine/tipiracil for the treatment of patients with metastatic colorectal cancer in routine clinical practice.曲氟尿苷/替匹嘧啶在常规临床实践中治疗转移性结直肠癌患者的有效性、安全性及预后因素
J Gastrointest Oncol. 2023 Apr 29;14(2):692-704. doi: 10.21037/jgo-22-517. Epub 2023 Feb 24.
9
RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer.RETRO-TAS研究，一项关于曲氟尿苷/替匹嘧啶治疗化疗难治性转移性结直肠癌的回顾性观察研究。
Biomedicines. 2023 Apr 24;11(5):1267. doi: 10.3390/biomedicines11051267.
10
Comparative Efficacy and Safety of Standard and Biweekly Trifluridine/Tipiracil Regimen in Patients With Colorectal Cancer.标准与双周曲氟尿苷/替匹嘧啶方案治疗结直肠癌患者的疗效和安全性比较
Anticancer Res. 2024 Mar;44(3):1219-1226. doi: 10.21873/anticanres.16917.

本文引用的文献

1
A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment.一项评估晚期实体瘤和不同程度肾功能损害患者中替氟尿苷/替匹嘧啶安全性和药代动力学的 I 期、开放性研究。
Cancer Chemother Pharmacol. 2021 Sep;88(3):485-497. doi: 10.1007/s00280-021-04308-z. Epub 2021 Jun 7.
2
Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer.转移性结直肠癌患者中氟尿嘧啶/替匹嘧啶的上市后监测研究。
Jpn J Clin Oncol. 2021 Apr 30;51(5):700-706. doi: 10.1093/jjco/hyaa243.
3
TAS-102 in metastatic colorectal cancer (mCRC): efficacy, tolerability, and quality of life in heavily pretreated elderly patients: a real-life study.
TAS-102治疗转移性结直肠癌（mCRC）：老年重度预处理患者的疗效、耐受性和生活质量：一项真实世界研究
Drugs Context. 2020 Sep 18;9. doi: 10.7573/dic.2020-6-3. eCollection 2020.
4
Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer.老年和年轻转移性结直肠癌患者开放性扩展准入计划中曲氟尿苷/替匹嘧啶的安全性。
Cancer Chemother Pharmacol. 2018 Dec;82(6):961-969. doi: 10.1007/s00280-018-3686-5. Epub 2018 Oct 22.
5
Biweekly Administration of TAS-102 for Neutropenia Prevention in Patients with Colorectal Cancer.每两周一次给予TAS-102预防结直肠癌患者中性粒细胞减少症。
Anticancer Res. 2018 Jul;38(7):4367-4373. doi: 10.21873/anticanres.12738.
6
Integrated safety summary for trifluridine/tipiracil (TAS-102).曲氟尿苷/替匹嘧啶（TAS-102）综合安全性总结
Anticancer Drugs. 2018 Jan;29(1):89-96. doi: 10.1097/CAD.0000000000000554.
7
TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study.TAS-102在转移性结直肠癌中的安全性：首个上市后监测研究结果
Clin Colorectal Cancer. 2016 Dec;15(4):e205-e211. doi: 10.1016/j.clcc.2016.04.004. Epub 2016 May 17.
8
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.TAS-102 治疗难治性转移性结直肠癌的随机试验。
N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325.
9
Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA.胸苷激酶1和脱氧尿苷三磷酸酶在将抗肿瘤核苷三氟尿苷和2'-脱氧-5-氟尿苷掺入DNA中的关键作用。
Int J Oncol. 2015;46(6):2327-34. doi: 10.3892/ijo.2015.2974. Epub 2015 Apr 20.
10
Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models.在小鼠模型中，重复口服给药TAS-102可使三氟尿苷大量掺入DNA并具有持续的抗肿瘤活性。
Oncol Rep. 2014 Dec;32(6):2319-26. doi: 10.3892/or.2014.3487. Epub 2014 Sep 17.